• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Life Science Market
Life Science News
Life Science Stocks
  • Life Science Market
  • Life Science News
  • Life Science Stocks

Superior Court Judge Pauses Spat over Alzheimer's Disease R&D

Morag Mcgreevey
Aug. 05, 2015 12:26PM PST
Life Science Investing

In a preliminary injunction, a Californian superior court judge has stepped between two major institutions arguing over a major Alzheimer’s disease research and development program that has the potential to benefit the pharmaceutical industry.

In a preliminary injunction, a Californian superior court judge has stepped between two major institutions arguing over a major Alzheimer’s disease research and development program that has the potential to benefit the pharmaceutical industry.
According to Fierce Biotech:

A superior court judge has demanded USC, which poached [Paul] Aisen and some of the program’s key researchers from UC San Diego in June, to take its hands off of the initiative until a related lawsuit from UCSD is resolved. That means returning to UCSD all data and systems related to the Alzheimer’s Disease Cooperative Study (ADCS), a National Institutes of Health-partnered initiative that has run 30 trials on potential new drugs since its foundation in 1991.
UCSD has managed ADCS since its inception, appointing the high-profile researcher Aisen to oversee the program in 2007. But USC lured Aisen away last month with the promise of a $500,000 salary, bringing with him 8 top Alzheimer’s researchers in what UCSD claims was an effort to wrest control of ADCS and get in line for the high-dollar grants attached to the program. In its lawsuit, UCSD claimed Aisen and his colleagues transferred loads of data from ADCS onto an Amazon hosting account of their own, repeatedly refusing to disclose the password to school officials.

Click here to read the full article on Fierce Biotech.

pharmaceutical-industry the-pharmaceutical-industry market-news
The Conversation (0)

Go Deeper

AI Powered
Scientist pouring blue liquid from a test tube into a flask in a lab.

Biotech Market Forecast: Top Trends for Biotech in 2026

Various colorful pills and tablets scattered from a brown bottle on a blue background.

Pharma Market Forecast: Top Trends for Pharma in 2026

Latest News

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

More News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES